Tag: Testosterone Undecanoate usage and stacksNearly every recreational user of anabolic steroids AAS testosterone undecanoate injection cycle the legal and health risks in order to improve his quality of life— a more impressive physique, greater confidence, or a competitive edge. Yet, despite the tangible benefits conferred by AAS, there ciclos anabolicos para mujer a number of pains that users face. In the practice of pharmacy, compliance is a major issue that determines the success of a drug treatment. Compliance means the patient following directions. To combat the habit of noncompliance, drug therapies are designed to be as effortless as possible.
Testosterone Undecanoate: Big Gains or Big Pain? | Muscular Development
Nearly every recreational user of anabolic steroids AAS accepts the legal and health risks in order to improve his quality of life— a more impressive physique, greater confidence, or a competitive edge. Yet, despite the tangible benefits conferred by AAS, there are a number of pains that users face. In the practice of pharmacy, compliance is a major issue that determines the success of a drug treatment. Compliance means the patient following directions.
To combat the habit of noncompliance, drug therapies are designed to be as effortless as possible. Thus, most oral drugs are once-daily; imagine the consequences of failing to take birth control as scheduled. Most women follow a once-daily birth control pill schedule, but it is inconvenient. Thus, long-acting birth control options have been developed that allow for the placement of hormone-infused silicone implants lasting five years, or an intramuscular injection lasting 12 weeks. The same delivery systems used to provide long-acting female sex steroid hormones can also be applied to male sex steroid hormones, such as AAS.
AAS users already depend upon injectable AAS rather than orals, due to their higher potency, convenience, and to avoid the liver toxicity inherent in 17alpha-alkyated steroids. The health and legal risks are abstractions to most recreational users; the most concrete pain associated with injectable AAS use is pain. Ask a type 1 diabetic about the impact of the condition on his life. Most become comfortable with dietary restrictions; it is the repeated injections and finger-pricks that are the least tolerable burdens.
Contrary to insulin which is injected under the skin, AAS are injected deep into muscle tissue; typically the gluteus butt muscle , but also shoulder or outer thigh. Even the longest-acting esters currently available in the U.
Bodybuilders avoid AAS lows by injecting more frequently, maintaining an anabolic concentration. During an AAS-only cycle, bodybuilders endure two or more intramuscular injections weekly, depending upon the dosing schedule and number of AAS stacked.
Competitive bodybuilders and athletes may compound this number with injections of insulin, growth hormone, inflammatory agents, prostaglandins, etc. A testosterone ester has been developed and used clinically in many countries possessing the desired profile. TU is capable of maintaining a steady concentration of testosterone for 12 weeks in most users, up to 14 weeks in some.
For American AAS users, or men receiving testosterone therapy, this sounds like nirvana— one shot every three months, rather than 12 or more. Unfortunately, the FDA is being uncharacteristically slow in approving TU, due to the rare report of transient short-term, like five minutes shortness of breath that has occurred when the depot is improperly injected.
If injected into a large vein, the globule could enter the pulmonary circulation lungs fairly intact, causing the sensation noted, until it is dispersed in the general circulation. Most AAS injections are limited to 2 ml or less. One issue with TU that may affect compliance is a greater frequency or severity of injection-related pain. Four ml may not seem like a large volume, a teaspoon has 5 ml.
However, when injected into the glute, 4 ml of an oil-filled depot can feel like one is sitting on a golf ball. Recently, a study was performed measuring relative pain associated with a 4 ml TU injection, and how long the pain lasts.
Those considering high-volume injections of other AAS, or hoping to acquire TU for recreational purposes, will likely find this worthy of note as well. Certain AAS, particularly veterinary preparations, are administered in low concentrations.
In the study, recently published in the Asian Journal of Andrology, Australian clinicians followed hypogonadal men receiving TU, administered as a single 4 ml intramuscular injection every 12 weeks; 43 returned during the study period for a scheduled injection, and their data were included in the analysis.
In reviewing these results, it is important to consider that the injections were provided in the clinic, by experienced nurses using proper injection protocol. The men were given a color-scale to represent the injection-related pain they experienced.
They scored pain at the site just prior to the injection, immediately following, three more times that day approximately four hours apart, then each morning for eight days. All of these men had received TU previously, so they all were aware of the nature of the procedure. As these men were all otherwise healthy, the pain score just prior to the injection was zero for nearly all subjects 96 percent , showing they were pain-free at the site of the injection.
Nearly all subjects felt some degree of pain immediately post-injection 80 percent , ranging from annoying 2 on a scale of 10 to moderately-severe pain score of 7. For most, the pain was worst immediately post-injection 58 percent , and resolved fairly quickly. In fact, none of the subjects reported that pain interfered with normal activities; in all cases, the pain resolved in three days or less. The authors compared this to an earlier study examining pain associated with a 1 ml intramuscular injection of testosterone enanthate TE.
In this, most men did not experience reportable pain; only 29 percent noted any injection-related discomfort. Two traits were noted that were associated with less pain— age and obesity.
Older men reported less pain than their younger counterparts; this may be due to reduced pain sensitivity that occurs with aging, or they may just be more stoic. In some men, this may be thicker than the length of the needle, causing the 4 ml depot to be dispersed among the less reactive adipose tissue fat , as opposed to the acutely sensitive muscle.
Though this has been noted to be an issue, it appears drug delivery may be equally effective when injected as an oil depot into fat or muscle. Most bodybuilders who have used injectables for many cycles can share the hassles: Some bodybuilders have had surgery to remove an abscess caused by the injection.
The advantage of injecting a single large bolus, rather than two or more smaller depots, is that a large globule releases the drug much more slowly. One large globule better protects the drug inside, insulating TU from esterases— enzymes that release testosterone from the pro-drug ester. TU increases testosterone concentration only after it is released from its attached ester.
It appears as though the U. Therapeutically, TU offers a very convenient and reliable means of keeping testosterone levels at a suitable concentration. The only requirement will be to attend a clinic for an unusually voluminous injection; some people may be able to administer this at home. For the recreational user, if one is not willing to undergo a 4 ml injection, the time course of dispersion will not be the week window seen with clinical use.
The kinetics of this drug given as a 1 ml injection would likely be similar to Deca-Durabolin nandrolone decanoate , which is esterified to a carbon tail, as opposed the carbon tail used in TU. TU is an exciting advance in testosterone replacement. However, for those looking to use it more frequently to maintain a supraphysiologic concentration over an extended period, TU may require big or at least annoying pains for big gains.
A pharmacokinetic study of injectable testosterone undecanoate in hypogonadal men. J Androl, Nov-Dec;19 6: Behre HM, Abshagen K, et al. Intramuscular injection of testosterone undecanoate for the treatment of male hypogonadism: Eur J Endocrinol, May; 5: Repeated intramuscular injections of testosterone undecanoate for substitution therapy in hypogonadal men. Clin Endocrinol Oxf , Dec;51 6: Treatment of male hypogonadism with testosterone undecanoate injected at extended intervals of 12 weeks: J Androl, May-Jun;23 3: Schubert M, Minnemann T, et al.
J Clin Endocrinol Metab , Nov;89 Yassin AA, Saad F. Treatment of sexual dysfunction of hypogonadal patients with long-acting testosterone undecanoate Nebido.
World J Urol, Dec;24 6: Morales A, Nieschlag E, et al. Clinical experience with the new long-acting injectable testosterone undecanoate.
Report on the educational symposium on the occasion of the 5th World Congress on the Aging Male, February , Salzburg, Austria.
Aging Male, Dec;9 4: Improvement of sexual function in men with late-onset hypogonadism treated with testosterone only. J Sex Med, Mar;4 2: Saad F, Kamischke A, et al. More than eight years' hands-on experience with the novel long-acting parenteral testosterone undecanoate.
Asian J Androl , May;9 3: Zitzmann M, Nieschlag E. Androgen receptor gene CAG repeat length and body mass index modulate the safety of long-term intramuscular testosterone undecanoate therapy in hypogonadal men. J Clin Endocrinol Metab , Oct;92 Minnemann T, Schubert M, et al. A four-year efficacy and safety study of the long-acting parenteral testosterone undecanoate.
Aging Male, Sep;10 3: Saad F, Gooren LJ, et al. A dose-response study of testosterone on sexual dysfunction and features of the metabolic syndrome using testosterone gel and parenteral testosterone undecanoate. J Androl, Jan-Feb;29 1: Saad F, Gooren L, et al. An exploratory study of the effects of month administration of the novel long-acting testosterone undecanoate on measures of sexual function and the metabolic syndrome.
Arch Androl , Nov-Dec;53 6: Moisey R, Swinburne J, et al. Serum testosterone and bioavailable testosterone correlate with age and body size in hypogonadal men treated with testosterone undecanoate mg IM--Nebido. Clin Endocrinol Oxf , Oct;69 4: Comparison of a new long-acting testosterone undecanoate formulation vs testosterone enanthate for intramuscular androgen therapy in male hypogonadism.
J Endocrinol Invest , Aug;31 8: Morgentaler A, Dobs AS, et al. Long acting testosterone undecanoate therapy in men with hypogonadism: